Skip to main content

Table 2 Radiotherapy dose constraints

From: Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)

Description

Naming Convention

Variable

Optimal

Mandatory

PTV

High dose radiotherapy arms

PTV6000

D99%

≥ 95%

≥ 90% (≥ 83%)a

PTV6000

D95%

≥ 97%

≥ 93% (≥ 90%)a

PTV5400

D99%

≥ 95%

≥ 90%

PTV5400

D95%

≥ 97%

≥ 93%

PTV6000 & PTV5400

DMax (0.1 cc)

≤ 110%

≤ 115%

PTV

Conventional dose radiotherapy arms

PTV5040

D99%

≥ 95%

≥ 90%

D95%

≥ 97%

≥ 93%

Dmax (0.1 cc)

≤ 105%.

≤ 107%

Kidney receiving higher dose

Kidney_R or Kidney_L

V20Gy

≤ 40%

≤ 45%

Combined Kidneys

V20Gy

≤ 30%

≤ 35%

Liver

Liver

V30Gy

≤ 30%

Mean

≤ 28Gy

≤ 30Gy

Stomach

Stomach

Dmax (0.1 cc)

≤ 58Gy

≤ 60Gy

V50Gy

<  5 cc

V45Gy

<  75 cc

Small Bowel

SmallBowel

Dmax (0.1 cc)

≤ 58Gy

≤ 60Gy

V50Gy

<  10 cc

V15Gy

<  120 cc

Duodenum

Duodenum

Dmax (0.1 cc)

≤ 58Gy

≤ 60Gy

V50Gy

<  10 cc

V15Gy

<  60 cc

Spinal Cord PRV

SpinalCord_05

Dmax (0.1 cc)

≤ 45Gy

  1. aWhen the gastrointestinal tract overlaps with a planned target volume, there is scope to reduce the dose in this region in order to prioritize gastrointestinal tract sparing. Abbreviations: PTV planned target volume